lung cancer
Conditions
Interventions
Thermal ablation of lung cancer lesions:Microwave ablation was performed on lung cancer patients.
Sponsors
Beijing Chaoyang Hospital, Capital Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1) Continuous presence (follow-up time > 6 months) of pure ground glass nodules or partially solid ground glass nodules, 2) Patients with cancer risk factors, such as family history, smoking, air pollution, etc., 3) High risk factors in imaging, such as lesion maximum diameter =15 mm, burr sign, lobular sign, pleural depression, vacuole sign, vascular cluster sign, GGN increase in dynamic observation (observation time > 6 months), and an increase in the reality component, etc., 4) Because of poor cardiopulmonary function or old age, patients cannot tolerate surgical resection or refuse surgery for their own reasons, 5) The multidisciplinary team (MDT) is jointly discussed, and the final diagnosis and treatment advice is formulated based on the multidisciplinary team (MDT) and shared decision making (SDM) with the patient, 6) Understand and sign the informed consent.
Exclusion criteria
Exclusion criteria: 1) Contraindications for bronchoscopy, including: Active massive hemoptysis; A recent myocardial infarction or an attack of unstable angina; Severe heart and lung dysfunction; Severe hypertension and arrhythmia; Uncorrectable bleeding tendency or severe coagulation dysfunction (such as platelets < 60×10^9/L), Uremia; Severe pulmonary hypertension; Severe superior vena cava obstruction syndrome; Intracranial hypertension; Acute cerebrovascular events; Aortic dissection or aortic aneurysm; Multiple pulmonary bulla; Extreme systemic failure; 2) Female patients who are breastfeeding or pregnant or preparing for pregnancy, 3) Patients with electromagnetic implantation devices in their bodies, 4) The subject is allergic to anesthetic; Or have a history of multiple severe allergies or hereditary allergies, 5) Participants who have participated in or are participating in drug clinical trials within 3 months before screening, or have participated in other medical device clinical trials within 30 days, 6) Other conditions deemed unsuitable for participation in this clinical trial by the investigator.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Proteomic; | — |
Secondary
| Measure | Time frame |
|---|---|
| Metabolomic;transcriptomics; | — |
Countries
China
Contacts
Public ContactWangFeng
Beijing Chaoyang Hospital, Capital Medical University
Outcome results
None listed